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a randomised study
Abstract
BACKGROUND: To compare early treatment effect of reduced fluence versus standard photodynamic
therapy (rPDT, sPDT, respectively) in combination with intravitreal triamcinolone (IVTA) in
neovascular age-related macular degeneration. METHODS: Forty patients received either sPDT (group
A, n = 20) or rPDT (group B, n = 20) each followed by same-day 4 mg IVTA. Patients were examined
at baseline, day 1, week 1, 4 and 12. Main outcomes were visual acuity, central retinal thickness (CRT),
choroidal perfusion and macular sensitivity (MS). RESULTS: Baseline characteristics were well
balanced in both groups (p>0.05). At week 12, patients in group A had a mean loss of -3.7 letters
compared with a gain of 3.4 letters in group B (p = 0.04, between both groups). Both treatment groups
showed a similar course regarding CRT as well as MS (p>0.05). In 70% (14/20) of group A and 15%
(3/20) of group B, a choroidal hypoperfusion in the area of treatment was observed after treatment
(p<0.001). In 70% of group A and 55% of group B, a repeat treatment was indicated at week 12 (p =
0.55). CONCLUSIONS: At month 3, the rPDT+IVTA group showed a significantly better visual
outcome, less alteration of the choroid and a trend for lower recurrence rate than the sPDT+IVTA group.
Further follow-up of this study will provide information on long-term functional results and treatment
durability.
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Background: To compare early treatment effect of reduced fluence versus standard 
photodynamic therapy (rPDT, sPDT, respectively) in combination with intravitreal 
triamcinolone (IVTA) in neovascular age-related macular degeneration.  
Methods: Forty patients either received sPDT (group A, n=20) or rPDT (group B, n=20) each 
followed by same day 4mg IVTA. Patients were examined at baseline, day 1, week 1, 4 and 
12. Main outcomes were visual acuity, central retinal thickness (CRT), choroidal perfusion 
and the macular sensitivity (MS). 
Results: Baseline characteristics were well balanced in both groups (p>0.05). At week 12, 
patients in group A had a mean loss of -3.7 letters compared with a gain of 3.4 letters in 
group B (p=0.04, between both groups). Both treatment groups showed a similar course 
regarding CRT as well as MS (p>0.05). In 70% (14/20) of group A and 15% (3/20) of group B 
a choroidal hypoperfusion in the area of treatment was observed after treatment (p<0.001). In 
70% of group A and 55% of group B a retreatment was indicated at week 12 (p=0.55). 
Conclusions: At month 3, RF PDT-IVTA group showed a significant better visual outcome, 
less alteration of the choroid and trend for lower recurrence rate than SF PDT-IVTA group. 
Further follow-up of this study will provide information on long-term functional results and 
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INTRODUCTION 
Several studies have proven that photodynamic therapy (PDT) damages the physiological 
choriocapillary bed surrounding the pathologic choroidal neovascularization (CNV) lesion. 
Choroidal angiography has demonstrated a permanent choriocapillary occlusion in 50% of 
treated eyes.[1] Choroidal ischemia consecutively induces a secondary angiogenic response 
with increased expression of vascular endothelial growth factor (VEGF). VEGF is the leading 
pathophysiological stimulus in the pathogenesis of neovascular age-related macular 
degeneration (AMD).[2]  The level of choroidal damage clearly correlated with the fluence 
used for the PDT treatment.[2]  As a result of this non-selective damage the CNV continues 
to progress and multiple retreatments are necessary to achieve stabilization of the disease. 
In pilot trials reduced fluence PDT (rPDT) as monotherapy was compared with a standard 
fluence (sPDT) regimen.[3,4] The patients in the reduce fluence group showed a clear trend 
for improved vision outcome and a significant lower rate of severe vision loss. However, it is 
still a matter of controversy whether a combination therapy with rPDT for the treatment of 
exudative AMD may result in similar or even better clinical/morphological outcomes. The aim 
of this study was to compare the treatment effect of rPDT and sPDT, both combined with 
IVTA for CNV secondary to AMD.  
 
METHODS 
This is a prospective, randomized, controlled, open-label, double-masked (examiner / 
patient) single center clinical trial. The study was performed at the Medical University of 
Vienna, Department of Ophthalmology and the study protocol adhered to the Helsinki 
Declaration and all patients had given written consent to the study participation following a 
comprehensive discussion of the purpose, risks and benefit of the procedures. The study 
was registered at the European Clinical Trials Database (EudraCT No.: 2005-000776-41).  
Primary and secondary outcomes were change in mean visual acuity and mean central 
retinal thickness (CRT) comparing both treatment groups. Enrolled were patients with 
neovascular AMD of any lesion type smaller than 4 disc areas, without any prior treatment for 
neovascular AMD, and a visual acuity of 20/40 to 20/800. Exclusion criteria were concomitant 
significant ocular disease that could compromise vision in the study eye, concurrent use of 
any investigational drug, intraocular surgery within 3 months of study enrolment, previous 
laser or PDT in the study eye and any history precluding the use of verteporfin, 
corticosteroids or both. Patients were randomized 1:1 to rPDT+IVTA or sPDT+IVTA. Patients 
in the group A (sPDT-IVTA) were treated with PDT according to the treatment of AMD with 
standard regimen  (the light dose of 50 J/cm2 was delivered over 83 seconds at a light 
fluency rate of 600 mW/cm2 in group A) followed by same day 4mg IVTA. Patients 
randomized to the group B (rPDT-IVTA) were treated with rPDT (the light dose of 25 J/cm2 
was delivered over 83 seconds at a light fluency rate of 300 mW/cm2 in group B) combined 
by same day 4 mg IVTA.[5] Retreatment was performed at 12 weeks, if leakage activity was 
present angiographically.  
Intravitreal Injection of the Triamcinolone Acetonide 
After disinfection of the periocular skin, topical anaesthesia was performed using 
oxybuprocain 2% and a lidocain 4%, and a sterile speculum was inserted. The conjunctival 
sac was disinfected using topical administration of betaisodine solution. Preservatives were 
washed out through a filter procedure using a micropore filter and BSS solution. A 27-gauge, 
1/2-inch needle, attached to a low-volume (e.g. tuberculin) syringe containing 4 mg (0.1 ml) 
of TA (Volon A; Bristol-Myers Squibb, S.p.A, Anagni, Italy) solution, was inserted through the 
pre-anesthetized conjunctiva and sclera approximately 3.5–4.0 mm posterior to the limbus, 
avoiding the horizontal meridian and aiming toward the center of the globe. The injection 
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volume delivered slowly and then the needle removed slowly to ensure that all drug solution 
is in the eye. Immediately following the intraocular injection, antimicrobial drops were 
administered. The patient was instructed to self-administer antimicrobial drops for 14 days 
following each intraocular injection of TA.   
Patients were routinely seen at baseline, and 1 day, 1 week, 4 and 12 weeks after the 
treatment. Evaluation included best corrected visual acuity (BCVA) according to the protocol 
established for the Early Treatment Diabetic Retinopathy Study (ETDRS), optical coherence 
tomography (OCT, StratusOCT, Zeiss-Meditec, D), FA (HRA 2, Carl Zeiss Meditec, Dublin, 
USA) with determination of leakage activity and measurement of the greatest linear diameter 
(GLD) in leakage area (µm), indocyanin green angiography (ICG-A, HRA 2, Carl Zeiss 
Meditec, Dublin, USA) macular sensitivity (MS) assessed by MP1 Microperimetry (Nidek Inc., 
Version MP1 SW 1.4.1. SP1) and a complete ophthalmologic exam using a standardized 
protocol.  
For statistic analysis ANOVA was used to compare mean visual acuity, mean CRT, mean 
MS of both treatment arms. For comparison of VA and CRT outcomes within each group to 
baseline the t-test was used. Retreatment rate and choroidal hypoperfusion were evaluated 
using Chi-Square test. The probabilities were all corrected for multiple testing, applying the 
Bonferroni-Holm step-down test (α = 0.05).[6]  
 
RESULTS 
Of the 40 patients (26 female and 14 male; 19 right eye and 21 left eye) included in this 
study, 20 patients were randomly enrolled in each study group. The mean age was 79.9±6.6 
years in the group A and 72.7±6.9 years in the group B (p=0.79). All 40 patients were 
included into the intent-to-treat population. Table 1 shows the baseline characteristics of both 
groups in detail. All patients completed the 12-week follow-up. 
Table 1: Baseline characteristics of both study groups. 
sPDT+IVTA: Standard fluence photodynamic therapy in combination with intravitreal 
triamcinolone 
rPDT+IVTA: Reduced fluence photodynamic therapy in combination with intravitreal 
triamcinolone 
CNV: choroidal neovascularisation 
GLD: greatest linear dimension identified by fluorescein angiography 
BCVA: best-corrected visual acuity 
SD: standard deviation 
ETDRS: Early Treatment Diabetic Retinopathy Study 
 sPDT+IVTA rPDT+IVTA P value 
N 
female/male 









Age (mean±SD) 79.2±6.6 79.7±6.9 0.79 
Occult CNV 
Classic CNV 









GLD (baseline/week12; µm, mean±SD) 3.4±1.4 / 3.4±1.2 3.6±1.1 / 3.4±0.9 > 0.05 
BCVA (ETDRS chart; letter; mean±SD) 36.4±18.2 37.5±10.5 0.81 
BCVA changes at week 12 
gain > 5 letters n (%) 










Macular thickness (mean±SD) 315±103 320±142 0.91 
Macular sensitivity (mean±SD) 5.0±2.5 5.4±3.2 0.69 
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Vision outcomes 
Mean VA of eyes enrolled into the sPDT+IVTA treatment arm decreased from 36.4 letters 
(20/200-2) at baseline to 27.1 letters (20/250-2) at day 1, and then returned to 33.5 letters 
(20/200-3) at week 1, 35.1 letters (20/200) at week 4 and 32.7 letters (20/250+2) at week 12. 
Mean VA of eyes enrolled into the rPDT+IVTA group showed a slightly decrease from 37.5 
letters (20/200+2) at baseline to 35.4 letters (20/200) at day 1 and then returned to 37.7 letters 
(20/160-2) at week 1, 36.3 letters (20/200+1) at week 4 and improved finally to 41.0 letters 
(20/160+1) at week 12. In both groups, changes in visual acuity show no statistically 
significant differences compared to baseline (p > 0.05) at all time points.  
 
At the primary endpoint of the study, patients in the sPDT+IVTA treatment group (group A) 
had a mean loss of -3.7 to a mean of 32.7 letters (p=0.19 to baseline; 95% CL: [-9.4; 2.0]) 
compared with a win of 3.4 to a mean of 41.0 letters (p=0.13 to baseline; 95% CL: [-1.1; 8.0]) 
in the rPDT+IVTA treatment group (group B) (figure 1). Comparing mean VA of both groups 
showed a statistically significant difference between both groups in favour of the rPDT+IVTA 
treated group at day 1 (p = 0.01, ANOVA between groups) and week 12 (mean difference of 
7.1, p = 0.04, ANOVA between groups).  
 
At week 12, 20% (4/20) of patients in group A and 5% (1/20) of patients in group B had lost 
at least 15 letters (3 lines). Improvement of vision of at least 5 letters (1 line) at week 12 was 
seen in 10% (2/20) of patients in group A and in 40% (8/20) of patients in group B (p=0.03 
Chi-Square test, table 1).  
 
Central retinal thickness 
Mean CRT (6 mm) showed similar changes for both groups up to week 12. In the 
sPDT+IVTA group mean CRT decreased from 315 µm at baseline, except for an increase to 
380 µm at day 1 (p=0.004), continuously to 247 µm at week 1 (p=0.001), 205 µm at week 4 
(p<0.001) and 236 µm at week 12 (p=0.014, mean difference to baseline: -80 µm; 95% CL: 
[18; 142µm]). Similarly, in the rPDT+IVTA group mean CRT decreased from 320 µm at 
baseline, except for an increase to 377 µm at day 1 (p=0.083), continuously to 236 µm at 
week 1 (p=0.037), 206 µm at week 4 (p=0.007) and 229 µm at week 12 (p=0.012, mean 
difference to baseline: -91 µm; 95% CL: [22; 160µm]). There was no statistically significant 
difference between both groups with regard to CRT (p > 0.05, ANOVA between groups).  
Further evaluation on CRT at 1 mm (figure 2) showed comparable results to CRT at 6 mm.  
 
Retreatment rate 
Based on the angiographically leckage activity, rPDT+IVTA group showed trend for lower 
recurrence rate than the sPDT+IVTA group at week 12; 14/20 patients (70%) in group A 
versus 11/20 patients (55%) needed a retreatment (p=0.55, Chi-Square test). The mean 
number of treatments including week 12 was 1.7 out of 2 possible treatments in the 
sPDT+IVTA treated group and 1.55 out of 2 possible treatments in the RF rPDT+IVTA 
treated group. 
Angiographic outcomes 
The mean GLD of leckage area was comparable between the 2 treatment groups at baseline 
and at the end of follow-up (table 1). ICG-A demonstrated less effect on the choroid in the 
rPDT+IVTA group, especially 1 day and 1 week after treatment. Figure 3 (top) shows a 
representative case treated with sPDT+IVTA. In 70% (14/20) of all sPDT+IVTA patients, a 
choroidal hypoperfusion in the area of treatment was observed 1 day after initial treatment. In 
30% the choroidal hypoperfusion in the area of treatment was ongoing up to week 4. In 
contrast, a choroidal hypoperfusion in the area of treatment was observed at day 1 in 15% 
(3/20) of patients, in the rPDT+IVTA group (p<0.001 compared to sPDT+IVTA group). Figure 
3 (bottom) shows a representative case treated with rPDT+IVTA. 
In sPDT+IVTA group, mean MS was 5.0±2.5 db at baseline and 5.0±2.7 db at week 12 
(p=0.94). In rPDT+IVTA group, mean MS was slightly increased from 5.4±3.2 at baseline to 
5.5±3.3 db at the end of follow-up time (p=0.87). There was no statistically significant 
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difference between both groups with regard to change in MS (0 db in group A versus +0.1 db 
in group B; p=0.95, ANOVA between groups). 
Safety 
Severe loss of vision of at least 30 letters (6 lines) was seen only in 1 patient (5%) in the 
sPDT+IVTA group (-39 letters compared to baseline, group A). 
Within the first 12 weeks of follow-up, there were no severe ocular or systemic side effects 
related to the treatment. PDT associated side effect was observed in 1 patient. This patient in 
the rPDT+IVTA group had back pain at the end of Verteporfin infusion. No surgical 
complications were observed during IVTA.  
There was no significant difference with regard to mean IOP between sPDT+IVTA and 
rPDT+IVTA (14.7 mmHg versus 14.5 mmHg at baseline, and 14.3 mmHg versus 16.6 mmHg 
at the end of follow-up time, respectively). A transient IOP rise (>25mmHg) was observed in 
2 patients (1 in each group) at week 1, treated with a local antiglaucoma therapy. 
 
DISCUSSION 
The present study investigates for the first time the effects of rPDT versus sPDT in 
combination with triamcinolone. All lesion types (predominantly classic, minimally classic and 
occult) were included. Short-term results of this investigation show even better treatment 
benefit of rPDT+IVTA for treatment of exudative AMD compared to sPDT+IVTA. At day 1 and 
week 12 there were significantly better results with regard to relative gain of BCVA in 
rPDT+IVTA treated group (figure 1). However, there was not significant difference with 
regard to macular sensitivity results. This may be related due to fixation difficulties and lack 
of compliance. CRT was increased in both treatment options at day one as expected due to 
an inflammation like reaction of the retina after PDT treatment. Interestingly, although a 
significant better BCVA results were observed, both treatment options showed similar 
anatomic improvements. There was no significant difference with regard to CRT between 
study groups at any follow-up time (figure 2).  
Actual parameters of PDT used for the treatment of CNV in AMD are those recommended by 
the TAP guidelines.[5,7] The present study clearly demonstrates that side effect of sPDT, s.a. 
hypoperfusion and choriocapillar thrombosis in treatment area are the result of the parameter 
selection and that such over treatment effects should be avoided. At day 1, patients treated 
with a combination of sPDT+IVTA showed a choriocapillary occlusion in 70% (14/20) of 
cases, whereas, in rPDT+IVTA group, only in 15% (3/20). Selecting optimal parameters 
allows differentiation between intended effects on the pathologic neovasculature and 
unwanted effects on the physiologic choroid. As shown in figure 3, the choriocapillaris was 
substantially less affected by treatment with the lower light dose, as seen in ICG-A at day 1 
and during further follow-up, which may be associated with less VEGF upregulation 
compared to standard light dose.  
Anti-VEGF therapy by intravitreal injection has shown promising results with regard to visual 
acuity.[8-10] However, an important drawback of anti-VEGF monotherapy is the significant 
high retreatment rate. Continued monthly anti-VEGF monotherapy entails continued safety 
risks associated with repeated intravitreal injections, cost, and inconvenience to patients.[11] 
Adding selective verteporfin therapy may improve angiographic and functional outcomes 
resulting in rapid stabilisation of the disease and lower retreatment rate. Inhibiting a 
physiologic angiogenic response secondary to choriocapillary hypoxia after standard PDT will 
most likely prevent choriocapillary recanalization and lead to more extensive and persistent 
choriocapillary closure. 
Safety of the combined treatments has been assessed previously.[12-14] Similarly, 
PDT+IVTA combination was well tolerated in our study. Only in 2 cases we observed an IOP-
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increase after IVTA, which was successfully controlled by local antiglaucomatous therapy. No 
retinal detachment, cataract development, or IVTA associated endophthalmitis were seen 
within this period of time. In addition, only 1 patient showed a decrease in BCVA > 30 letters 
in sPDT+IVTA group. 
The present study was started and the patient’s recruitment was closed before intravitreal 
use of Ranibizumab was approved in EU. Although anti-VEGF monotherapy is currently the 
standard of care in most situations, due to drawbacks of anti-VEGF monotherapy new 
treatment modalities using PDT, such as PDT and anti-VEGF or PDT, corticosteroids and 
anti-VEGF combinations appear to be attractive alternatives.[11,15] Selecting optimal 
parameters of PDT in these combination strategies may result in better results, which could 
be shown in the present study.  
This is the first pilot study performed with a prospective, randomized, controlled and double-
blinded design showing efficacy and safety of reduced fluence PDT in combination with 
IVTA. Short-term results suggest that a reduced light dose of PDT may result in a better 
safety profile, due to reduced damage to the collateral choroidal vasculature. The results 
support the theory that an occlusion of the surrounding choriocapillaris is not necessary to 
achieve closure of the CNV lesion, but that the vasooclusive effects at the level of the CNV 
and physiologic choroid may be separated by choosing an appropriate dosimetry. Long-term 
follow-up is required to evaluate the safety and treatment efficacy of both treatment 
modalities. The reduced fluence approach appears to offer superior visual benefit together 
with a reduced need for retreatment at 3 months follow-up. 
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Figure 1: Relative visual acuity gain during 12 week follow-up time (mean ± standard error 
of mean). * p< 0.05 between both study groups. 
 
Figure 2: Course of central retinal thickness (central 1 mm). * p< 0.05 compared to baseline 
for group A, ** p< 0.05 compared to baseline for both groups. 
 
Figure 3: Representative cases of each study group. Top; patient treated with combination 
treatment of standard fluence photodynamic therapy (sPDT) and intravitreal triamcinolone 
(IVTA) shows a typically hypoperfusion and choriocapillar thrombosis in the area of treatment 
by indocyanin green angiography at day 1. Bottom; patient treated with combination 
treatment of reduced fluence PDT (rPDT)+IVTA shows no hypoperfusion in the area of the 
treatment. 
Early FA: Fluorescein angiogram at 1-2 minutes 
Late FA: Fluorescein angiogram at 10 minutes 
Early ICG: Indocyanin green angiogram at 1-2 minutes 
Late ICG: Indocyanin green angiogram at 25 minutes 
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